Skip to main content

Daiichi Sankyo Initiates Phase 3 study of CS-3150 for Treatment of Essential Hypertension

 

Clinical courses

Daiichi Sankyo Company, Limited  announced that it has initiated a Phase 3 pivotal study of CS-3150 (esaxerenone (r-INN)), its non-steroidal, selective novel mineralocorticoid receptor (MR) antagonist, for patients in Japan with essential hypertension.

In March 2006, Daiichi Sankyo and Exelixis entered into a research collaboration agreement to discover, develop and commercialize novel therapies targeted for the MR. Under the terms of the agreement, Daiichi Sankyo has exclusive development, manufacturing and commercialization rights for the compounds worldwide.

CS-3150 is one of the in-licensed compounds identified during the research collaboration with Exelixis, and has subsequently been developed by Daiichi Sankyo.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email